From Investing.com:

Gilead Sciences has announced its acquisition of CymaBay Therapeutics for $4.3 billion, aiming to expand its liver disease drugs portfolio. The deal will give Gilead access to CymaBay’s lead drug candidate, seladelpar, for treating primary biliary cholangitis. CymaBay had submitted a marketing application to the FDA for the drug in December, prompting a halt in its shares ahead of the announcement.



Read more: Drugmaker Gilead to acquire CymaBay for $4.3 billion By Reuters